Keywords: New Zeland, PHARMAC, Novo Nordisk, NovoMix, NovoSeven, Glucagen
New Zealand considers listing of NovoMix 30 and NovoSeven RT and amendment for Glucagen Hypokit
Article | 02 May 2012
The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to fund NovoMix 30 FlexPen and NovoSeven ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
